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Abstract
Aims/hypothesis Previous literature documents controversial
results for the impact of dehydroepiandrosterone (DHEA) in
glucose metabolism. We aimed to assess the associations be-
tween serum levels of DHEA and its main derivatives DHEA
sulphate (DHEAS) and androstenedione, as well as the ratio of
DHEAS to DHEA, and risk of type 2 diabetes.
Methods We used data on serum levels of DHEA, DHEAS
and androstenedione from 5189 middle-aged and elderly men
and women from the prospective population-based Rotterdam
Study. Type 2 diabetes was defined as a fasting blood glucose
≥7.0 mmol/l or a non-fasting blood glucose ≥11.1 mmol/l.
Results During a median follow-up of 10.9 years, 643 patients
with incident type 2 diabetes were identified. After adjusting
for age, sex, cohort, fasting status, fasting glucose and insulin,
and BMI, both serum DHEA levels (per 1 unit natural log-
transformed, HR 0.76, 95% CI 0.67, 0.87) and serumDHEAS
levels (per 1 unit natural log-transformed, HR 0.82, 95% CI
0.73, 0.92) were inversely associated with risk of type 2 dia-
betes in the total population. Further adjustment for alcohol,
smoking, physical activity, prevalent cardiovascular disease,
serum total cholesterol, use of lipid-lowering medications,
systolic BP, treatment for hypertension, C-reactive protein,
oestradiol and testosterone did not substantially affect the as-
sociation between DHEA and incident type 2 diabetes (per 1
unit natural log-transformed, HR 0.80, 95% CI 0.65, 0.99),
but abolished the association between DHEAS and type 2
diabetes. Androstenedione was not associated with risk of
type 2 diabetes, nor was DHEAS to DHEA ratio.
Conclusions/interpretation DHEA serum levels might be an
independent marker of type 2 diabetes.
Keywords Androstenedione . DHEA . DHEAS . Food
supplement . Independent marker . Type 2 diabetes
Abbreviations
CRP C-reactive protein
CVD Cardiovascular disease
DHEA Dehydroepiandrosterone
DHEAS Dehydroepiandrosterone sulphate
HDL-C HDL-cholesterol
LDL-C LDL-cholesterol
PPAR Peroxisome proliferator-activated receptor
RCT Randomised controlled trial
RS-I Rotterdam Study cohort 1
RS-II Rotterdam Study cohort 2
SBP Systolic BP
SHBG Sex hormone-binding globulin
TC Total cholesterol
TG Triacylglycerol
TSH Thyroid-stimulating hormone
Introduction
Dehydroepiandrosterone (DHEA), mostly present as its
sulphated ester (DHEAS), is the most abundant circulating
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adrenal steroid hormone in healthy adults. In both men and
women, peak serum levels of DHEA and DHEAS occur
around 25 years of age, with levels declining steadily from
the third decade onwards [1]. Similarly, both glucose tolerance
and insulin sensitivity decrease with ageing [2].
DHEA is available as a health food supplement in the USA,
but previous literature on the effects of supplemental DHEA
on glucose metabolism in healthy humans is controversial
[3–6]. Evidence from animal studies indicates that DHEA
treatment could result in increased insulin-induced glucose
uptake in rat models of type 2 diabetes and moderate the
severity of diabetes [7, 8]. Along the same lines, a randomised
controlled trial (RCT) of elderly women and men with an age-
related decrease in DHEA showed that DHEA replacement
reduced abdominal fat and improved insulin sensitivity [9].
Further, but not all, RCTs have reported positive effects of
DHEA supplementation on reducing body fat and improving
glucose metabolism [10–14]. In observational studies, levels
of DHEAS have also been associated with lower BMI and
visceral fat in women [15], and plasma glucose and serum
insulin concentrations in non-diabetic men [16].
Despite extensive research on DHEA and insulin action,
information about the role of DHEA in type 2 diabetes risk
remains scarce. Studies prospectively investigating the asso-
ciation between DHEA or DHEAS and type 2 diabetes are
limited and have been conducted mainly in women [17, 18].
Sex differences have been suggested, and it remains unclear
whether the effects of DHEA on risk of type 2 diabetes are
different in women and men [11–14, 19, 20]. We therefore
aimed to prospectively examine the associations between
DHEA and its main derivatives DHEAS and androstenedione,
as well as the ratio of DHEAS to DHEA, and incident type 2
diabetes in healthy middle-aged and elderly men and women.
Materials and methods
Study populationThe Rotterdam Study is a population-based
cohort study of individuals aged 45 years and over who live in
the Ommoord district of Rotterdam, the Netherlands. The ra-
tionale and design of the Rotterdam Study is described else-
where [21]. In brief, all inhabitants of the Ommoord district
aged 55 years or older were invited to participate (n=10,215).
At baseline (1990–1993), 7983 participants were included
(RS-I). In 2000, an additional 3011 participants were enrolled
(RS-II), consisting of all persons living in the study district
who had turned 55 years of age. Follow-up visits were held
every 3–5 years. For this study, we used measurements of
DHEA and its derivatives that were made during the third visit
of the first cohort (RSI-3) and the baseline examinations of the
second cohort (RSII-1).
The Rotterdam Study has been approved by the Medical
Ethics Committee according to the Wet Bevolkingsonderzoek:
ERGO (Population Study Act: Rotterdam Study), executed by
the Ministry of Health, Welfare and Sports of the Netherlands.
All participants gave informed consent for their participation in
the study and for information to be obtained separately from
treating physicians and pharmacies.
Population under analysis The present study used data from
the third visit of the first cohort (RSI-3) and the baseline exam-
inations of the second cohort (RSII-1). Overall, 6923 partici-
pants were eligible for blood measurements and available for
type 2 diabetes follow-up (3923 postmenopausal women and
3000 men). Of these, 937 individuals (483 postmenopausal
woman and 454 men) with prevalent diabetes were excluded.
Furthermore, for 797 participants (422 postmenopausal women
and 375 men), there was no information on DHEA and its
derivatives, so they were therefore excluded from the analysis,
leaving 5189 participants for analysis (see electronic supple-
mentary material [ESM] Fig. 1). Concentrations of sex steroids
were assessed in non-fasting samples from 270 of these partic-
ipants. A sensitivity analysis was performed excluding this
group from the analysis.
Ascertainment of type 2 diabetes The participants were
followed from the date of the baseline visit to the research
centre onwards. At baseline and during follow-up, cases of
type 2 diabetes were ascertained through active follow-up
using general practitioners’ records, hospital discharge letters
and serum glucose measurements from Rotterdam Study
visits, which take place approximately every 4 years [22].
Type 2 diabetes was defined, according to current WHO
guidelines, as a fasting blood glucose ≥7.0 mmol/l, a non-
fasting blood glucose ≥11.1 mmol/l (when fasting samples
were absent) or the use of blood glucose-lowering medication
[23]. Information regarding the use of blood glucose-lowering
medication was derived from both structured home interviews
and linkage to pharmacy records [22]. At baseline, more than
95% of the Rotterdam Study population was covered by the
pharmacies in the study area. All potential events of type 2
diabetes were independently adjudicated by two study physi-
cians. In cases of disagreement, consensus was sought from an
endocrinologist. Follow-up data were complete until 1
January 2012.
Hormone measurements Sex hormone-binding globulin
(SHBG) was measured using the Immulite 2000XPi platform
(Siemens, Los Angeles, CA, USA), while thyroid-stimulating
hormone (TSH) was measured on the Vitros Eci (Ortho
Diagnostics, Raritan, NJ, USA). Oestradiol was measured
using a COBAS 8000 Modular Analyzer (Roche Diagnostics,
Rotkreuz, Switzerland). The corresponding interassay CV was
<7%.
Androstenedione, testosterone and DHEASweremeasured
on a Waters XEVO TQ-S system (Waters, Milford, MA,
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USA) using the CHSMSMS Steroids Kit (Perkin Elmer,
Turku, Finland). The interassay CVs of androstenedione, tes-
tosterone and DHEAS were <6.5%, <5% and <5.9%, respec-
tively. Although assessment of blood measurements, includ-
ing sex steroids, was performed on fasting samples, some of
the participants came to the research centre in a non-fasting
state.
Covariates Information on current health status, medical his-
tory, medication use and smoking behaviour was obtained at
baseline for all the participants. Participants were asked
whether they were currently smoking cigarettes, cigars or
pipes. Alcohol intake was assessed in grams of ethanol per
day. History of cardiovascular disease (CVD) was defined as a
history of CHD (myocardial infarction, revascularisation, cor-
onary artery bypass graft surgery or percutaneous coronary
intervention) or stroke and was verified from the general prac-
titioner’s medical records. Information regarding the use of
hormone replacement therapy was derived from structured
home interviews. Parental history of diabetes was collected
by trained research assistants during home visits.
BP was measured in the sitting position on the right upper
arm with a random-zero sphygmomanometer. Physical height
(m) and body weight (kg) were measured at baseline with the
participants standing without shoes and heavy outer garments.
BMI was calculated as weight divided by height squared
(kg/m2). All biochemical variables were assessed using
fasting serum. Insulin, glucose, total cholesterol (TC),
HDL-cholesterol (HDL-C), triacylglycerol (TG) and
C-reactive protein (CRP) were measured using a COBAS
8000 Modular Analyzer (Roche Diagnostics). The corre-
sponding interassay CVs were insulin <8%, glucose <1.4%,
lipids <2.1% and CRP <16.9%. LDL-cholesterol (LDL-C)
level was estimated indirectly from measurements of TC,
and HDL-C and TGs by means of the Friedewald equation
[24]. Physical activity was assessed using an adapted version
of the Zutphen Physical Activity Questionnaire [25]. Every
activity mentioned in the questionnaire was attributed a met-
abolic equivalent value according to the 2011 codes [26].
Statistical analysis Person-years of follow-up were calculated
from study entrance (March 1997 to December 1999 for RSI-
3, February 2000 to December 2001 for RSII-1) to the date of
diagnosis of type 2 diabetes, death or the censor date (date of
last contact of the living), whichever occurred first. Follow-up
lasted until 1 January 2012.
Cox proportional hazard modelling was used to evaluate
whether DHEA, DHEAS, androstenedione, and DHEAS to
DHEA ratio were associated with type 2 diabetes. HRs and
95% CIs were reported. The proportional hazard assumption
of the Cox model was checked by visual inspection of log
minus log plots and by performing a test for heterogeneity
of the exposure over time. There was no evidence of violation
of the proportionality assumption in any of the models (p for
time-dependent interaction terms >0.05). To account for age
and sex differences in serum levels of DHEA, DHEAS and
androstenedione, we used sex hormone levels adjusted for age
and sex by using the residual method [27]. All sex hormones
variables were assessed in separate models, continuously and
in tertiles. To study the relations across increasing tertiles,
trend tests were computed by entering the categorical vari-
ables as continuous variables in multivariable Cox’s propor-
tional hazard models. To achieve approximately normal dis-
tribution, skewed variables (DHEA, DHEAS, androstenedi-
one, testosterone, oestradiol, SHBG, CRP, TSH, glucose and
insulin) were natural log-transformed.
In the base model (model 1), we adjusted for age, sex,
cohort (I and II), fasting status (fasting sample vs non-
fasting sample). Model 2 included all factors in model 1 as
well as BMI (continuous), glucose (continuous) and insulin
(continuous). Model 3 included all the covariates from model
2 as well as further potential intermediate factors including
metabolic risk factors (TC, systolic BP [SBP; continuous],
treatment for hypertension [yes vs no] and use of lipid-
lowering medications [yes vs no]), lifestyle factors (alcohol
intake [continuous], smoking status [current vs former/never]
and physical activity), prevalent CVD (yes vs no) and CRP
level (continuous). We also controlled for upstream precursor
hormones (ESM Fig. 2), which may act as confounders. Thus,
DHEAwas adjusted in all models that included either DHEAS
or androstenedione. Effect modifications of sex hormones by
BMI and sex were tested in the final multivariable model in
addition to performing stratified analysis.
We also performed several sensitivity analyses: (1) further
adjusting for hormones including downstream metabolites that
might be casual intermediates, such as oestradiol and testoster-
one; (2) further adjusting for SHBG; (3) substituting BMI for
waist circumference; (4) substituting TCwith HDL-C, TGs and
LDL-C; (5) further adjusting for parental history of diabetes
(6); further adjusting for TSH; (7) further adjusting by exclud-
ing individuals with type 2 diabetes within the first 3 years of
follow-up (n=99/643 cases); (8) excluding participants with
non-fasting samples (n=270); (9) further adjustment for hor-
mone replacement therapy; and (10) further adjustment for free
androgen index. A multiple imputation procedure (n=5 impu-
tations) was used to impute the missing data.
Moreover, we compared the effect of DHEA and its deriv-
atives on 10-year risk prediction of type 2 diabetes by study-
ing the discrimination. Discrimination is the ability of a pre-
dictive model to assign a higher risk to individuals who will
develop an event in 10 years compared with those who will
not. We quantified discrimination for both models by calcu-
lating the c-statistic difference between the base model and the
models that additionally included DHEA or its derivatives
[28]. There is not yet a unique established risk prediction
model for type 2 diabetes; therefore, as a base model, we used
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Wilson’s risk score, including age, sex, parental history of
diabetes and BMI [29]. To perform this analysis, we used a
combinat ion of ‘ foreign ’ (ht tps : / /cran.r-project .
org/web/packages/foreign/foreign.pdf) and ‘survC1’
(https://cran.r-project.org/web/packages/survC1/survC1.pdf)
R packages. All other analyses were done using IBM SPSS
Statistics software version 21.0.0.1 (SPSS, Chicago, IL, USA)
and R software version 3.0.1 (R Foundation for Statistical
Computing, Vienna, Austria). A p value <0.05 was
considered statistically significant.
Results
Table 1 summarises the baseline characteristics of 5189 par-
ticipants who were free from diabetes at baseline, including
3018 postmenopausal women and 2171 men.
Survival analysis During a median follow-up time of
10.9 years, 643 incident cases of type 2 diabetes were identi-
fied. After adjusting for age, sex, cohort, fasting status, fasting
glucose and insulin, and BMI, both serumDHEA levels (per 1
unit natural log-transformed, HR 0.76, 95%CI 0.67, 0.87) and
serum DHEAS levels (per 1 unit natural log-transformed, HR
0.82, 95% CI 0.73, 0.92) were inversely associated with risk
of type 2 diabetes (Table 2) in the total population. Further
adjustment for alcohol intake, smoking status, physical activ-
ity, prevalent CVD, serum TC, use of serum lipid-reducing
medications, SBP and treatment for hypertension, and CRP
concentration did not materially affect the association between
DHEA and incident type 2 diabetes (per 1 unit natural log-
transformed, HR 0.76, 95%CI 0.67, 0.87), but it abolished the
association between DHEAS and type 2 diabetes (Table 2).
Androstenedione was not associated with risk of type 2 dia-
betes, and neither was the DHEAS to DHEA ratio (Table 2).
Sensitivity analysis In the sensitivity analysis, none of the
associations was affected by the following: (1) further
adjusting for hormones including downstream metabolites
that might be casual intermediates such as oestradiol and tes-
tosterone; (2) further adjustment for SHBG; (3) substituting
BMI for waist circumference; (4) substituting TC for HDL-C,
TGs and LDL-C; (5) further adjustment for parental history of
diabetes; (6) further adjustment for TSH level; (7) exclusion of
individuals with type 2 diabetes within the first 3 years of
follow-up; (8) excluding participants with non-fasting sam-
ples (n=270); (9) further adjustment for hormone replacement
therapy; and (10) further adjustment for free androgen index
(Table 3). In addition, no significant interactions were found
for any of the hormones or their ratio with sex and BMI in the
stratification analysis (Table 3).
The c-statistic of the Wilson’s base model for 10-year risk
of type 2 diabetes was 0.637 (0.609, 0.666). When we added
DHEA to the model, the c-statistic improved to 0.638 (0.612,
0.665), with a difference of 0.001 (−0.003, 0.005). DHEA and
its derivatives did not improve Wilson’s base model (ESM
Table 1).
Discussion
In this large prospective population-based cohort study, we
found that serum level of DHEAwas inversely associatedwith
risk of type 2 diabetes, independent of established diabetes
risk factors including BMI, fasting glucose, insulin and CRP.
We did not find any evidence regarding sex differences in this
association. The association also remained significant after
including in the model downstream sex steroid metabolites
such as testosterone and oestradiol, cited as risk factors for
Table 1 Selected characteristic of study participants from the Rotterdam
Study
Variable Value
Characteristic, n 5189
Age (years) 69 ± 8.3
Males, n (%) 2171 (41.8)
Fasting status, n (%) 4911 (94.6)
Current smokers, n (%) 632 (12.2)
Alcohol intake (g/day) 2.1 (11.6)
BMI (kg/m2) 26.7 ± 3.8
Waist circumference (cm) 92.7 ± 11.5
Prevalent CVD, n (%) 586 (11.3)
Parental history of diabetes, n (%) 463 (8.9)
Oestradiol (pmol/l) 62.8 (137.5)
Total testosterone (nmol/l) 1.4 (24.1)
SHBG (nmol/l) 55.5 (93.1)
TSH (mU/l) 1.8 (4.9)
Insulin (pmol/l) 66 (145)
Glucose (mmol/l) 5.5 (1.8)
CRP (nmol/l) 0.0162 (0.0981)
TC (mmol/l) 5.8 ± 0.9
LDL-C (mmol/l) 3.7 ± 0.9
HDL-C (mmol/l) 1.4 ± 0.4
Use of serum lipid-reducing agents, n (%) 605 (11.7)
Hormone replacement therapy, n (%) 140 (2.7)
Free androgen index 2.5 (31.8)
TGs (mmol/l) 1.4 (0.8)
SBP (mm/Hg) 142 ± 21
Treatment for hypertension, n (%) 1087 (20.9)
DHEA (nmol/l) 8.3 (20.6)
DHEAS (nmol/l) 1819.2 (4672.7)
Androstenedione (nmol/l) 2.5 (4.1)
Values are mean ± SD, or median (interquartile range), unless otherwise
indicated
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type 2 diabetes [30]. In our study, no independent association
was found between DHEAS, androstenedione or DHEAS to
DHEA ratio and risk of type 2 diabetes.
A study of 1612 postmenopausal women prospectively ex-
amined the association between DHEA and risk of type 2
diabetes and showed no effect [17]. Our study included both
men and women, a larger number of incident cases of type 2
diabetes (643 vs116), a longer follow-up ( median 10.9 vs
4.7 years) and a comprehensive assessment of hormones.
Another study byMather et al showed no association between
DHEA and incidence of diabetes, but it was conducted in
individuals at high risk of diabetes and involved a short
follow-up (median 3.0 years) [31]. Similar to our findings,
although an inverse association was suggested in a nested
case–control study of 718 postmenopausal women, DHEAS
was not statistically significantly associated with a lower risk
of type 2 diabetes [18]. In addition, a recent study, including
1258 community-dwelling men and women reported no asso-
ciation between DHEAS and type 2 diabetes overall, but after
stratification by sex, higher serum DHEAS levels were pro-
tective against type 2 diabetes in men, but not in women [19].
Previous studies in animal have documented therapeutic
effects of DHEA in mice used as a model of diabetes [7].
Owing to the striking beneficial effects, observed mostly in
animals, of DHEA against diabetes, as well as against other
chronic conditions such as cancer, obesity and CVD, DHEA is
now available as a food supplement in retail stores [32–34].
The aforementioned conditions are mostly observed in ageing
and as accompanying the natural steady decline of DHEA
from the third decade onward [1, 35].
However, animal data should be translated with caution to
human physiology, taking into consideration the contrast be-
tween the lower amounts of DHEA in laboratory animals and
the distinctly human role of DHEA, which has a pattern of
biosynthesis specific to higher primates [36]. Until recently,
there has been conflicting evidence in the literature concerning
the effect of DHEA on glucose metabolism in healthy humans.
Human data have shown that DHEA administration increases
[9, 11], has no effect [13, 20] or decreases [37] insulin sensi-
tivity, leaving the role of DHEA in glucose metabolism and
development of type 2 diabetes unclear. Moreover, Villareal
et al [9] found that DHEA supplementation for 6 months
Table 2 Associations of androstenedione, DHEA andDHEASwith risk of type 2 diabetes in postmenopausal women and men in the Rotterdam Study
(n = 5189)
Variable Tertile 1 Tertile 2 Tertile 3 Continuous p value p trend
Androstenedione
Cases 216 230 197
Model 1, HR, 95% CI 1 1.09 (0.90, 1.31) 0.92 (0.76, 1.12) 0.92 (0.77, 1.09) 0.3 0.4
Model 2, HR, 95% CI 1 1.07 (0.89, 1.29) 0.82 (0.67, 0.99)* 0.82 (0.69, 0.97) 1.8 × 10−2 4.5 × 10−2
Model 3, HR, 95% CI 1 1.19 (0.97, 1.46) 0.98 (0.77, 1.26) 0.98 (0.78, 1.24)a 0.9 0.9
DHEA
Cases 236 206 201
Model 1, HR, 95% CI 1 0.79 (0.66, 0.96) 0.76 (0.63, 0.92)* 0.79 (0.69, 0.89) 3.0 × 10−4 5.0 × 10−3
Model 2, HR, 95% CI 1 0.84 (0.69, 1.02) 0.73 (0.60, 0.89)* 0.76 (0.67, 0.87) 5.6 × 10−5 1.0 × 10−3
Model 3, HR, 95% CI 1 0.84 (0.69, 1.02) 0.73 (0.60, 0.89)* 0.76 (0.67, 0.87)a 8.7 × 10−5 2.0 × 10−3
DHEAS
Cases 226 203 214
Model 1, HR, 95% CI 1 0.86 (0.71, 1.04) 0.91 (0.76, 1.09) 0.88 (0.79, 0.99) 3.5 × 10−2 0.3
Model 2, HR, 95% CI 1 0.79 (0.65, 0.96)* 0.83 (0.69, 1.01) 0.82 (0.73, 0.92) 1.0 × 10−3 6.0 × 10−2
Model 3, HR, 95% CI 1 0.91 (0.74, 1.12) 1.13 (0.88, 1.45) 0.94 (0.79, 1.12)a 0.5 0.3
DHEAS/DHEA
Cases 198 215 230
Model 1, HR, 95% CI 1 1.08 (0.89, 1.31) 1.23 (1.02, 1.49)* 1.14 (0.96, 1.34) 0.1 3.0 × 10−2
Model 2, HR, 95% CI 1 1.11 (0.92, 1.35) 1.15 (0.95, 1.39) 1.03 (0.88, 1.22) 0.6 0.1
Model 3, HR, 95% CI 1 1.11 (0.92, 1.36) 1.15 (0.95, 1.41) 1.03 (0.87, 1.22)a 0.7 0.1
Model 1: adjusted for age, sex, cohort, fasting status
Model 2: model 1 + insulin, glucose and BMI
Model 3: model 2 + alcohol intake, smoking status, physical activity, prevalent CVD, serum TC, use of serum lipid-reducing agents, SBP, treatment for
hypertension, C-reactive protein and sex hormones adjusted for each other (androstenedione adjusted for DHEA, DHEAS adjusted for DHEA)
aNo significant interaction between sex and hormone or ratio (p> 0.05)
* p< 0.05
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decreased visceral adiposity, whereas in a 2 year trial, Nair et al
[20] did not observe any benefits of DHEA.
Our findings on a protective role of DHEA against type 2
diabetes provide epidemiological evidence in agreement with
previous claims for positive effects of DHEA in type 2 diabe-
tes (DHEA has previously also been called ‘elixir of youth’).
Pertaining to its mechanisms of action, DHEA is a peroxisome
proliferator-activated receptor (PPAR) α agonist [30].
Tenenbaum et al found that bezafibrate, a PPARα receptor
ligand, reduced the incidence and delayed the onset of type
2 diabetes in patients with impaired fasting glucose levels
[38]. DHEA and DHEAS have been shown to be insulin
sensitisers [39], whereas there is less evidence that insulin
alters DHEA or DHEAS levels [40]. Perrini et al found that
DHEA increases glucose uptake in both human and 3 T3-L1
adipocytes by stimulating GLUT4 and GLUT1 translocation
to the plasma membrane [41]. Another study of patients with
type 2 diabetes concluded that DHEA administration
counteracted oxidative imbalance and advanced glycation
end-product formation [42]. In addition, in rat models, it has
been shown that DHEA improves glucose uptake via activa-
tion of protein kinase C and phosphatidylinositol 3-kinase
[43]. Another possible mechanism for the prevention of type
2 diabetes by DHEA is an improvement in endothelial func-
tion [14], which is implicated in the development of insulin
resistance [44].
Previous studies have suggested sex differences for
DHEA and its derivatives in type 2 diabetes [11, 12,
19, 45]. DHEA concentrations are approximately twice
as high in women, whereas DHEAS levels are higher in
men [46]. In our study, we observed the protective ef-
fect of DHEA in men and women, slightly more prom-
inent in women than in men, but the interaction with
sex was not significant. The HRs showed the same di-
rection in both women and men, but the association was
not significant in men. This might be explained by the
smaller number of incident cases of type 2 diabetes in
men (n= 270) compared with women (n= 373) in our
study.
Very little is known regarding the role of plasma levels of
androstenedione in the pathology of type 2 diabetes. O’Reilly
et al showed that serum androstenedione level, other than in its
role as a precursor of testosterone, is a useful tool for
predicting metabolic risk in women with polycystic ovary
Table 3 Sensitivity analysis of sex hormones and risk of type 2 diabetes in postmenopausal women and men in the Rotterdam Study (n= 5189)
Variable Androstenedione DHEA DHEAS DHEAS/DHEA
Multivariable modela 0.99 (0.79, 1.24) 0.76 (0.67, 0.88)* 0.94 (0.80, 1.11) 1.03 (0.87, 1.21)
Multivariable model + sex hormones for each other
(oestradiol and testosterone included in the model)
1.01 (0.80, 1.27) 0.80 (0.65, 0.99)* 0.94 (0.79, 1.10) Not included
Multivariable model + SHBG 0.96 (0.78, 1.19) 0.77 (0.67, 0.88)* 0.89 (0.77, 1.03) 0.96 (0.83, 1.12)
Multivariable model + waist circumference 0.98 (0.78, 1.23) 0.76 (0.67, 0.87)* 0.95 (0.80, 1.12) 1.04 (0.88, 1.22)
Multivariable model + HDL-C + TG + LDL-C 0.98 (0.78, 1.24) 0.77 (0.68, 0.88)* 0.97 (0.82, 1.14) 1.06 (0.89, 1.25)
Multivariable model + serum TSH 0.97 (0.77, 1.22) 0.76 (0.67, 0.87)* 0.96 (0.81, 1.13) 1.05 (0.89, 1.23)
Multivariable model + parental history of diabetes 0.98 (0.79, 1.22) 0.77 (0.67, 0.88)* 0.95 (0.82, 1.09) 1.02 (0.88, 1.18)
Multivariable model excluding the first 3 years of follow-up 1.06 (0.83, 1.36) 0.76 (0.66, 0.88)* 0.97 (0.81, 1.16) 1.06 (0.89, 1.27)
Multivariable model excluding non-fasting participants 0.96 (0.77, 1.21) 0.76 (0.67, 0.88)* 0.91 (0.78, 1.06) 0.98 (0.84, 1.15)
Multivariable model + hormone replacement therapy 0.98 (0.79, 1.23) 0.76 (0.67, 0.87)* 0.95 (0.82, 1.11) 1.03 (0.88, 1.19)
Multivariable model + free androgen index 0.95 (0.75, 1.20) 0.76 (0.67, 0.87)* 0.90 (0.76, 1.07) 1.01 (0.85, 1.19)
Incident diabetes cases (n= 643)b
BMI (kg/m2)a
<25 (n= 134)b 0.75 (0.45, 1.24)c 0.81 (0.59, 1.11)c 1.21 (0.82, 1.78)c 1.29 (0.89, 1.87)c
25–29.9 (n= 323)b 1.20 (0.87, 1.66)c 0.80 (0.66, 0.97)c* 0.96 (0.77, 1.21)c 1.02 (0.81, 1.29)c
≥30 (n= 186)b 0.84 (0.54, 1.30)c 0.67 (0.53, 0.86)c* 0.75 (0.55, 1.03)c 0.88 (0.65, 1.21)c
Sexa
Men (270)b 1.17 (0.80, 1.71) 0.82 (0.66, 1.03) 1.02 (0.77, 1.35) 1.10 (0.84, 1.44)
Women (373)b 0.88 (0.66, 1.17) 0.74 (0.63, 0.88)* 0.91 (0.74, 1.12) 0.99 (0.80, 1.22)
Values are + 1 natural log increase
aMultivariable model adjusted for variables in model 3 of Table 2
b Incident diabetes cases for each BMI stratum or sex, from 643 cases in total
c p for interaction >0.05; * p< 0.05
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syndrome [47]. Our study is the first to investigate the associ-
ation of serum androstenedione levels with incident type 2
diabetes, and has shown no association.
Adrenocorticotropic hormone regulates the production of
both DHEA and DHEAS, which, once secreted into the
bloodstream, are carried bound to albumin. Although
DHEAS, the sulphated form of DHEA, can be converted to
DHEA, and vice versa, they have some important peculiarities
[48]. Concentrations of DHEAS are between 250 and 500
times higher than concentrations of DHEA in women and
men, respectively. This difference in concentrations between
DHEA and DHEAS depends mainly on the fact that DHEAS
is only slowly cleared from the blood, with a clearance rate of
13 l/day, while DHEA is rapidly cleared at a rate of approxi-
mately 2000 l/day. Therefore, DHEAS has a half-life of 10–
20 h, while the half-life of DHEA is 1–3 h. Diurnal variation
of DHEA exhibits a similar pattern to that of cortisol secretion,
reaching a peak in the early morning. DHEAS levels are con-
sidered not to have a diurnal variation [49].
The strengths of our study include its prospective design,
the long follow-up and the comprehensive adjustment for a
broad range of possible confounders.Moreover, this is the first
population-based study to investigate the associations be-
tween the serum levels of DHEA and its main derivatives
and incident type 2 diabetes in both men and women. We also
performed several sensitivity analyses such as excluding the
first 3 years of follow-up to avoid a potential bias of undiag-
nosed disease at baseline. Furthermore, the diagnosis of inci-
dent diabetes was made by standardised blood glucose mea-
surements at the repeated study centre visits and electronic
linkage with pharmacy dispensing records in the study area.
However, our study has some limitations. Our population
was aged 55 years and older, and therefore results should be
generalised to a younger age only with caution. HbA1c and
OGTTs were not measured in our study population, which
would have strengthened our results. In contrast to DHEAS
and its other derivatives, DHEA has a pronounced diurnal
rhythm and exhibits a morning elevation similar to cortisol.
However, the diurnal secretory pattern of DHEA is more sta-
ble and the day-to-day variability less stable than cortisol [50].
Furthermore, this study was carried out in middle-aged and
elderly patients, and in older age hormone levels are more
stable over time (intraclass correlation 0.75, 0.88 and 0.66
for DHEA, DHEAS and androstenedione respectively) [50].
In addition, the Rotterdam Study mainly includes individuals
of European ancestry (98%). Thus, our findings may not be
extendable to non-white groups.
We conclude that higher serum levels of DHEA are inde-
pendently associated with a decreased risk of developing type
2 diabetes in healthy populations of both men and postmeno-
pausal women. These prospective data suggest that DHEA
may play a role in the pathogenesis of type 2 diabetes, which
may have important implications for preventive interventions.
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